Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (4284)	4/15/2003 6:55:01 AM
From: Icebrg	Read Replies (2) \| Respond to of 10345

>>Ms. Parker was in Dr. Gadde's study, in the placebo group>> That's the problem trying to beat the placebo group. I do suppose however, that in Ms Parker's case the positive effects were seen after she had finished her participation in the study and had started to consume her free supply of Zonegran. As for patents, that's not really my department, but I found a reference indicating that the patent is valid until Dec 21, 2018. myorangebook.com From what I have seen there are risks for quite serious side-effects when Zonegran is used. On the third hand however - if Elan is trying to develop the drug to treat migraine, they are perhaps not so bad after all. Zonegran is btw. not a drug developed by Elan. They have licensed it from Dainippon. Erik Edit Some more information on Zonegran. centerwatch.com I see that in the above documentation loss of appetite is listed as a negative side-effect.